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Abstract 
The cGAS–STING signalling axis, comprising the synthase for the second messenger cyclic 
GMP–AMP (cGAS) and the cyclic GMP–AMP receptor stimulator of interferon genes (STING), 
detects pathogenic DNA to trigger an innate immune reaction involving a strong type I 
interferon response against microbial infections. Notably however, besides sensing microbial 
DNA, the DNA sensor cGAS can also be activated by endogenous DNA, including extranuclear 
chromatin resulting from genotoxic stress and DNA released from mitochondria, placing 
cGAS–STING as an important axis in autoimmunity, sterile inflammatory responses and 
cellular senescence. Initial models assumed that co-localization of cGAS and DNA in the cytosol 
defines the specificity of the pathway for non-self, but recent work revealed that cGAS is also 
present in the nucleus and at the plasma membrane, and such subcellular 
compartmentalization was linked to signalling specificity of cGAS. Further confounding the 
simple view of cGAS–STING signalling as a response mechanism to infectious agents, both 
cGAS and STING were shown to have additional functions, independent of interferon 
response. These involve non-catalytic roles of cGAS in regulating DNA repair and signalling via 
STING to NF-κB and MAPK as well as STING-mediated induction of autophagy and lysosome-
dependent cell death. We have also learnt that cGAS dimers can multimerize and undergo 
liquid–liquid phase separation to form biomolecular condensates that could importantly 
regulate cGAS activation. Here, we review the molecular mechanisms and cellular functions 
underlying cGAS–STING activation and signalling, particularly highlighting the newly emerging 
diversity of this signalling pathway and discussing how the specificity towards normal, 
damage-induced and infection-associated DNA could be achieved. 
Introduction 
Cell intrinsic recognition and defence systems against foreign genetic material encompass an 
ancient and fundamental feature of living systems. A first line of defence in mammals is 
orchestrated by the innate immune system. Germline-encoded pattern recognition receptors 
(PRRs) detect various pathogen and damage-associated molecular patterns(PAMPs and 
DAMPs). Their activation elicits signalling cascades that lead to the initiation of cell 
autonomous defence mechanisms, as well as the production of soluble mediators, such as 
type I interferons and pro-inflammatory cytokines (Box 1). Type I interferons play a central 
role in impeding viral propagation, hence their production is typically governed by PRRs that 
have evolved to sense viral infection. By inducing the expression of interferon-stimulated 
genes, type I interferons boost cell autonomous defence mechanisms in an autocrine manner, 
and furthermore can spread antiviral immunity and activate the adaptive immune system. 
Cytosolic DNA is a potent activator of a type I interferon response1,2 (Fig. 1). Under normal 
conditions, DNA is confined to the nucleus and mitochondria, and is rapidly degraded by 
nucleases in the cytosol and endolysosomal compartments. Following infections, for example, 
increased amounts of intracellular DNA are detected in a pathway that involves cyclic GMP–
AMP synthase (cGAS; also known as MB21D1)3,4, a member of the nucleotidyl transferase 
(NTase) enzyme family5 that functions upstream of stimulator of interferon genes (STING). 
cGAS normally resides as inactive protein in the cell. Upon binding to DNA, cGAS undergoes a 
conformational change to an active state and produces the second messenger cyclic GMP–
AMP (cGAMP) from ATP and GTP6,7,8,9, which is subsequently detected by the cyclic-
dinucleotide sensor STING3,4,10, an ~40-kDa dimeric transmembrane protein at the 
endoplasmic reticulum (ER)11. Binding of cGAMP activates STING, which then translocates to 
the Golgi and activates TANK-binding kinase 1 (TBK1). TBK1 then phosphorylates itself, STING 
and, subsequently, the interferon regulatory factor 3 (IRF3) transcription factor. IRF3 
dimerizes, enters the nucleus and triggers the production of type I interferons and, 
subsequently, the expression of interferon-stimulated genes that together orchestrate 
antiviral defence mechanisms. 
Over the past years it became evident that the cGAS–STING axis is activated not only by non-
self DNA, such as DNA from DNA viruses or retroviruses, intracellular bacteria and protozoa, 
but also by extracellular, mitochondrial and nuclear DNA that gain access to the cytosol. 
Increased cytosolic DNA levels due to, for example, mitotic stress in cancers, radiation therapy 
and cellular senescence or in autoimmune disorders, such as Aicardi–Goutières syndrome and 
systemic lupus erythematosus, can lead to constitutive and systemic activation of cGAS–
STING, resulting in chronic inflammation and pathology12,13,14,15. Understanding molecular and 
cellular details of cGAS–STING signalling is therefore of considerable biomedical importance. 
Intense efforts are underway to develop both inhibitors and activators of cGAS and STING, in 
order to, respectively, treat autoimmune and inflammatory diseases or to activate the innate 
immune response in immune silent (‘cold’) tumours to induce antitumour immunity16 (Box 2). 
Although the original models suggested that cGAS is simply activated when it is exposed to 
DNA in the cytosol, recent studies showed that the situation is more complex. cGAS not only 
is found in the cytosol but has a multifaceted cellular distribution that involves localization at 
the cell membrane and in the nucleus. In the nucleus, cGAS is exposed to chromosomal DNA, 
raising important questions of to what extent it is activated there, how it is regulated and how 
it distinguishes chromatin from infection-associated DNA. Both cGAS activation and STING 
activation were observed to lead to formation of oligomeric structures and, in the case of 
cGAS, even liquid–liquid phase separation-driven condensates were described. Phase-
separated condensates emerge as a new organizing principle of cells and are supramolecular 
assemblies or membraneless organelles with liquid-like dynamic properties, whereby the 
phase-separated protein and nucleic acid are enriched in the condensate and depleted 
otherwise17. In the case of cGAS and STING, oligomers and condensates could play important 
roles in defining substrate selectivity and ensuring a switch-like response to infections, 
because they bias the system towards long and accessible (that is, not covered by, for 
example, nucleosomes) DNA that promotes formation of large assemblies. Furthermore, type 
I interferons are an evolutionarily recent development in vertebrates, whereas cGAS–STING 
and related systems are much more ancient and are found in primitive eukaryotes and even 
prokaryotes, raising questions regarding the evolutionary roots and ancient functions of the 
cGAS–STING system. 
Here, we review the emerging multifaceted nature of both upstream and downstream parts 
of cGAS–STING signalling, discuss models of activation that explain cytosolic and nuclear 
functions, and point to current limitations and open questions in understanding the regulation 
of this pathway. 
 
Discovery of DNA sensing by cGAS–STING 
STING (also named MITA, MPYS and ERIS) is an evolutionary conserved transmembrane 
protein that is found beyond vertebrates, down to primitive metazoa and protozoa18. It was 
discovered by two independent cDNA overexpression screens aimed at identifying open 
reading frames that would trigger antiviral gene expression11,19. Around the same time, it was 
proposed that STING (there referred to as MPYS) would be associated with major 
histocompatibility complex class II (MHC II) and be involved in pro-apoptotic signalling20. 
Although all of the initial studies agreed on the fact that STING is a transmembrane protein, 
there was no consensus on its subcellular location and its exact membrane topology. 
Subsequent studies, however, confirmed the initial concept that STING is an ER-
resident11membrane passing molecule with its carboxy-terminal (C-terminal) part facing the 
cytosol21. Functional studies agreed on the fact that STING exerted TBK1–IRF3-dependent 
antiviral activity, yet the respective upstream signal leading to its signalling function remained 
unclear. Although STING was postulated to be generally involved in DNA and RNA virus 
recognition11,19, a more pronounced phenotype was indeed observed for DNA viruses and 
synthetic double-stranded DNA (dsDNA) ligands. In fact, stimulation with double-stranded 
RNA or AT-rich dsDNA proved to exert STING-independent antiviral activity via the PRRs MDA5 
and RIG-I, respectively22. Overall, STING emerged as the long-sought link between cytosolic 
DNA recognition and antiviral immunity, and initially it was postulated that STING directly 
detects DNA itself23. However, subsequent studies revealed that STING acts as a receptor for 
bacterial cyclic dinucleotides10, which appeared to be at odds with its function in DNA 
recognition. The solution to this conundrum came from the pioneering work of Chen and co-
workers with the discovery of cGAS, which acts as a direct DNA receptor and produces the 
endogenous cyclic dinucleotide second messenger molecule cGAMP to, in turn, activate 
STING3,4. In metazoans, there are enzymes that are highly related to cGAS — on the level of 
sequence, structure and function — including other MAB21 family proteins (such as MAB21L1, 
MAB21L2 and MAB21L3) as well as RNA-recognizing 2ʹ–5ʹ-oligoadenylate synthases (OASs). 
Interestingly, cGAMP is structurally related to bacterial cyclic dinucleotides (for example, c-di-
GMP and c-di-AMP), highlighting the role of these molecules in signalling across phylogenetic 
kingdoms. However, cGAMP contains an unusual 2ʹ–5ʹ phosphodiester bond between the 2ʹO 
of guanosine and the 5ʹO of adenosine that appears to be, up until now, specific to eukaryotes 
(a feature also represented by OASs)6,7,8 (Fig. 1). cGAS is also related to, for example, bacterial 
dinucleotide cyclase DncV, comprising a pathogenicity factor from Vibrio cholerae. Together, 
these different enzymes form a ‘CD-NTase’ (cGAS-DncV) subclade of NTases24. Recent results 
uncover an increasing number of nucleotide-based small molecules produced from these 
enzymes25 and reveal widespread bacterial cGAS–STING (or cGAS-like enzymes coupled to 
other effectors) as components of antiviral defence systems26. 
In hindsight, the discovery of the activity of cGAS as a DNA receptor explained earlier 
observations that overexpression of cGAS (then known as C6Orf150) showed broad antiviral 
effects27. In the following sections, we discuss in more detail how cGAS and STING function. 
 
cGAS structure and localization 
cGAS, an ~520-amino-acid protein containing an unstructured, highly basic ~160-amino-acid 
amino-terminal (N-terminal) domain along with a globular ~360-amino-acid domain, was first 
purified from cytosolic extracts of a murine fibrosarcoma cell line using a functional assay for 
DNA-induced cGAMP synthase activity and shown to function as a cytosolic DNA sensor with 
direct DNA-binding activity3. Subsequent X-ray crystallography allowed visualization of the 
cGAS structure and how it interacts with DNA. Concomitantly, subcellular distribution of cGAS 
was investigated, revealing that in addition to the initially described cytoplasmic localization, 
cGAS is also bound to the inner leaflet of the plasma membrane and present in the nucleus. 
Basic overview of cGAS structural features 
The catalytic domain of cGAS consists of two structural lobes with the active site at their 
interface. Lobe 1 includes the evolutionary conserved core β-sheet of NTases, also found in, 
for example, DNA polymerases, that harbours the conserved acidic residues involved in the 
Mg2+-dependent catalytic transfer of the nucleoside phosphate onto the hydroxyl acceptor. 
Lobe II completes the active site and adds interactions for nucleoside–triphosphate donor 
binding. 
Initial structural studies showed that free cGAS (not bound to DNA) does not have a suitably 
structured active site8,28,29, whereas DNA binding induces a global conformational change and 
structures a catalytic activation loop in the interface between the two lobes, such that 
substrate ATP and GTP and metal ions can bind in a catalytically proficient manner8,29. 
Subsequent work showed that in order to adopt a stable active conformation, cGAS needs to 
assemble into a dimer, with two DNA strands sandwiched between the two cGAS 
protomers30,31 (Fig. 1). This cGAS dimer formation is an allosteric process that is coupled to 
switching cGAS from the catalytic inactive state to the catalytic active state and is promoted 
by further clustering32,33 (see below). Each protomer of the dimer harbours two DNA binding 
sites denoted ‘A’ and ‘B’30,31, and each of the two DNA molecules engaged by the dimer is 
bound to site A of one cGAS protomer and to site B of the respective other protomer. In total, 
cGAS covers around 16–18 bp of DNA and this binding occurs in a sequence-independent 
fashion. 
cGAS subcellular localization 
Although initial studies detected a minor amount of cGAS in nuclear and perinuclear regions, 
it was concluded that cGAS is a cytoplasmic protein and that this cytoplasmic 
compartmentalization dictates specificity of cGAS towards non-self DNA, in that it prevents 
cGAS from interacting with nuclear or mitochondrial DNA (which are also recognized by cGAS; 
see next section). Recent reports challenge this simplistic view by showing that cGAS can be 
found within the nucleus (Fig. 2). Nuclear cGAS foci have been observed initially in human 
fibroblasts and keratinocytes transfected with plasmid DNA34, in the context of nuclear 
membrane breakdown35,36, but also in non-mitotic cells under certain conditions, where cGAS 
was observed to enter the nucleus upon DNA damage37. More recent work indicates that cGAS 
constitutively resides in the nucleus38,39,40, and even that cGAS is predominantly localized 
within the nucleus and tightly sequestered to chromatin40. The N-terminal, unstructured 
domain was shown to constitute a dominant cytoplasmic retention signal, which — when 
functionally perturbed — resulted in increased nuclear localization39,41. The nuclear 
localization of cGAS was ascribed to its DNA binding activity38,39 and to a highly basic patch on 
the catalytic domain involved in chromatin retention40. 
Another study also found that cytosolic cGAS does not appear to reside in a free pool but is 
largely localized to the inner leaflet of the plasma membrane41 (Fig. 2). Here, the N-terminal 
domain appears to be responsible for membrane sequestration and shown to interact 
preferentially, but not exclusively, with phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) 
on the inner plasma membrane leaflet in the steady state. cGAS lacking the membrane-
localizing N-terminal domain showed increased spontaneous activity and higher nuclear 
retention, but decreased activation by modified vaccinia Ankara (a dsDNA virus). Based on 
these findings, it was proposed that not only could membrane sequestration help keep cGAS 
away from endogenous DNA but membrane localization could help cGAS detect more rapidly 
or efficiently DNA from viruses that enter the cell through endocytosis41. 
Clearly, more quantitative studies of cellular localization are still needed to obtain a better 
understanding of cGAS cellular distribution. Nevertheless, a picture emerges where cGAS is 
not only found in the cytosol but appears to be constitutively, and perhaps even preferentially, 
located in the nucleus, suggesting that detection of self-DNA is not prevented through 
confinement to compartments or organelles, but rather by sequestering it to structures such 
as chromatin. The mode in which cGAS that does reside in the nucleus is kept inactive despite 
interacting with DNA has not yet been revealed. However, sequestration in an inactive state 
could be an important mechanism for an optimal dynamic range and a rapid response without 
the need for de novo protein synthesis: it could serve to limit the ‘noise’ of the system by 
keeping soluble cGAS concentrations low, and allowing rapid replenishment of the soluble 
fraction when agonistic DNA is recognized, thereby ensuring a high dynamic range of 
subsequent signalling. 
 
cGAS recognized DNA sources 
The foundational studies of cGAS identified its requirement for responding to DNA virus 
infection3 and microbial DNA remains the primary trigger for cGAS activation. However, 
besides infection-associated DNA entering the cytosol from viral or bacterial sources, cGAS 
has now been found to interact or at least co-localize with various types of endogenous self-
DNA. These include cytosolic DNA of nuclear and mitochondrial origin, DNA in cytosolic 
micronuclei and chromatin in the nucleus (Fig. 2). On a structural level, DNAs that activate 
cGAS range from long dsDNA molecules32,42,43 to single-stranded DNA (ssDNA) with local 
secondary structure and short, synthetic DNA with G-rich single-stranded overhangs43 as well 
as RNA–DNA hybrids (but RNA–DNA hybrids constitute suboptimal agonists)44. Here, we 
describe which forms of DNA cGAS encounters in different compartments and what is known 
about their role in cGAS activation. 
Microbial DNA 
Known viral non-self DNAs detected by cGAS include, among others, DNA from herpes simplex 
virus and vaccinia virus45, HIV46 and cytomelagovirus47,48 (reviewed previously49). The cGAS–
STING axis has also been shown to play an important role in RNA virus control, but this likely 
seems to be an indirect effect though mitochondrial DNA (mtDNA) release (see below). cGAS 
also senses DNA from intracellular bacteria including Chlamydia trachomatis50, 
Mycobacterium tuberculosis51,52,53, Francisella novicida54, Listeria monocytogenes55 and 
Neisseria gonorrhoeae56. However, some intracellular bacteria also release cyclic 
dinucleotides that can directly activate STING57,58, so which PAMP is predominantly detected 
by the cGAS–STING axis for intracellular bacteria detection is still a matter of debate. Finally, 
cGAS contributes to parasite control59 by detecting the genomic DNA of protozoans such as 
Plasmodium. 
Microbial DNAs are often shielded from accessing the cytosol and are packaged into, for 
example, nucleoids or tight protein–DNA structures that, like chromatin, are presumably poor 
activators of cGAS. It is generally assumed that occasional ruptures of the bacteria cells or viral 
structures could lead to exposed cytosolic DNA that allows binding of cGAS and switching it to 
an active state. Similar considerations can be drawn for engulfed tumour-derived DNA (see 
below), which probably no longer has a fully assembled, proper nucleosomal packaging once 
it enters the cytosol. 
Although it is often assumed that recognition of microbial DNA occurs in the cytosol, the 
substantial nuclear presence of cGAS opens the possibility for nuclear sensing of viruses. 
Indeed, in the case of HIV-2, DNA sensing by cGAS occurs in the nucleus, assisted by a host 
factor denoted NONO (non-POU domain-containing octamer binding protein)60. NONO, a 
multifunctional protein, binds nucleic acids and HIV capsid proteins in the nucleus and thus 
might direct cGAS to HIV DNA. Nuclear localization of cGAS suggests now that detection of 
viral DNA could be a more general feature as many DNA and retroviruses replicate in the 
nucleus and might have more accessible DNA during the integration and replication phases. 
Besides NONO, other host proteins could contribute to sensing of viruses and the diverse 
nature of their non-self ssDNA and dsDNA (Table 1). Polyglutamine binding protein 1 (PQBP1), 
a host protein involved in RNA splicing, has been found in screens in dendritic cellsto interact 
with reverse-transcribed HIV-1 ssDNA and cGAS for efficient IRF3 activation61. CCHC-type zinc-
finger protein 3 (ZCCHC3) and GTPase-activating protein SH3 domain-binding protein 1 
(G3BP1) were identified as cofactors that enhance cGAS binding to dsDNA62,63. The recognition 
of viral DNA by cGAS is likely more complex, as cGAS, NONO and PQBP1 are physically linked 
through a nuclear ribonucleoprotein protein complex containing NEAT1 long non-coding RNA 
that regulates cGAS–STING activation64. The mechanisms underlying these RNA and protein 
cofactors and the regulatory complexes of cGAS-mediated pathogenic DNA recognition need 
further investigation and could range from their more direct roles in stabilizing 
macromolecular interactions of nucleic acids with cGAS to indirect functions in regulating 
cellular localization, DNA access or formation of cGAS biomolecular condensates (see section 
Mechanism of cGAS activation). 
In addition to triggering cGAS activation in the infecting cell, microbial infection can also 
promote the sorting of their DNA into extracellular vesicles, which are taken up by bystander, 
neighbouring cells to induce paracrine ‘spreading’ of cGAS activation between cells. Such 
paracrine cGAS–STING signalling was shown to occur between cells infected by intracellular 
bacteria and activated T cells, and resulted in compromised antibacterial defence owing to 
increased apoptosis of T cells in response to cGAS–STING signalling65. 
Extracellular self-DNA 
Extracellular self-DNA can enter the cytosol through increased extracellular DNA supply, for 
example in the context of increased cell death, or perturbed phagocytic digestion. Here, well-
studied paradigms that imply involvement of DNA as a substrate are deficiencies for 
extracellular or lysosomal DNases, which result in the translocation of self-DNA into the 
cytoplasm and subsequent cGAS–STING activation12. At the same time, self-DNA can also be 
delivered into the cytosol via extracellular vesicles (exosomes and microvesicles) (Fig. 2). For 
instance, exosomes can carry tumour-derived DNA to dendritic cells66. Once delivered to the 
dendritic cell — either via exosomes or more directly from the extracellular space via 
endocytosis — such tumour-derived DNA can trigger dendritic cell activation through the 
cGAS–STING pathway in the tumour microenvironment and increase antitumour 
immunity66,67,68. Yet, in this context, it has to be noted that tumour cell-derived cGAMP has 
also been shown to trigger STING activation in the tumour microenvironment, leading to an 
antitumour response of natural killer cells69. 
Mitochondrial DNA 
A potential source of cytosolic, cGAS-agonistic self-DNA is mtDNA70 (Fig. 2). Leakage of mtDNA 
into the cytosol occurs in the context of intrinsic apoptosis, where mitochondrial membrane 
integrity is compromised by the formation of BAK/BAX macropores and mitochondrial outer 
membrane permeabilization that mainly serves to release mitochondria-sequestered 
cytochrome c, which initiates the apoptotic caspase cascade. However, in the case of 
apoptotic stimuli, mitochondrial outer membrane permeabilization has been shown not only 
to lead to cytochrome c release but also to allow extrusion of the inner mitochondrial 
membrane to the cytosol, which is associated with mitochondrial inner membrane 
permeabilization and mtDNA efflux to the cytosol, where it could bind to cGAS71(Fig. 2).Yet, 
under normal conditions, this apoptotic mtDNA efflux does not result in cGAS activation, 
because concomitant activation of the intrinsic apoptosis cascade specifically antagonizes 
cGAS–STING signalling by proteolytic cleavage of cGAS by effector caspases72,73. Interestingly, 
the ability of cGAS to be activated by mtDNA can be functionally disconnected from the 
apoptotic cascade. Apparently, mtDNA leakage leading to cGAS activation and cytochrome c 
release resulting in intrinsic apoptosis seem to obey to different thresholds. In that regard, it 
has been observed that cGAS activation by leaked mtDNA can already occur before the 
concomitant cytochrome c release results in apoptotic cell death. Numerous scenarios have 
been described in which such mechanisms seem to be at play. For example, depletion of the 
mtDNA packaging factor TFAM and subsequent mtDNA leakage activates the cGAS–STING 
axis70, revealing a cellular response to mitochondrial stress through detection of mtDNA. Also, 
microbial pathogens can indirectly trigger cGAS–STING activation through the induction of 
mitochondrial stress that results in mtDNA leakage. In this regard, herpes simplex virus70 
infection triggers the release of mtDNA, activating cGAS. A similar scenario is true for dengue 
virus, a positive single-stranded RNA virus that does not produce DNA in the course of its life 
cycle and, thus, has no capacity for autonomous cGAS induction. Yet, by triggering the release 
of mtDNA, dengue virus mounts an antiviral response in a cGAS–STING-dependent 
fashion74,75. These observations likely explain how the DNA sensor cGAS counteracts the 
replication of numerous RNA viruses76 and why the cGAS–STING axis is specifically targeted by 
certain RNA viruses77. Finally, mtDNA release can also be triggered by cytokine signalling 
cascades78, but the mechanisms by which mtDNA is released from the mitochondria in these 
circumstances remains unclear, warranting further studies in this area. Overall, these studies 
suggest that mitochondrial stress can be a broadly triggered cue in eliciting a cellular response 
through cGAS–STING, effectively widening the surveillance role of this cascade. 
Nuclear chromatin 
As mentioned above, recent work implies that cGAS is constitutively nuclear and chromatin 
sequestration is in fact a critical process to prevent its spurious activation38,39,40 (Fig. 2). A first 
report using longer reconstituted nucleosomal arrays implied cGAS activation by chromatin in 
vitro79, suggesting that cGAS is activated by nucleosomes. However, two recent studies 
reported that nucleosome core particles (mononucleosomes without linker DNA) do not lead 
to cGAS activation although cGAS binds them with high affinity36,38. The discrepancy in these 
studies is as yet unclear, but it is conceivable that cGAS activation by nucleosomal arrays was 
not caused by nucleosomes, but by linker DNA or residual free DNA. 
On the one hand, cGAS sequestration to chromatin is highly salt resistant, suggesting that 
cGAS interaction with chromatin is not, or not only, mediated by DNA but might involve 
protein–protein interactions as well40. On the other hand, cGAS residues critically involved in 
nuclear retention are part of a prominent DNA-binding site of cGAS (site B, see above and Fig. 
1), raising the possibility that nucleosomal DNA binds cGAS involving this cluster, but does not 
trigger an active conformation. In any case, the mode of how cGAS is sequestered to 
chromatin is still unknown and requires future studies. 
Cytosolic chromatin and micronuclei 
Important sources of agonistic, cell-intrinsic self-DNA detected by cGAS are cytosolic 
micronuclei as well as isolated cytosolic chromatin or DNA structures arising from defective 
DNA replication, repair and mitosis79,80,81,82,83 (Fig. 2). Micronuclei contain chromatin 
fragments surrounded by a nuclear envelope-like structure and formed as a result of, for 
example, DNA double-strand breaks, mitotic errors or problems in DNA replication, leading to 
chromatin fragments, or they may even contain entire non-segregated chromosomes that 
recruit their own nuclear envelopes during mitosis. Micronuclei often undergo envelope 
collapse due to structural defects in the underlying lamina84, enabling cGAS to access the DNA. 
However, it was recently found that cGAS in micronuclei can originate from nuclear cGAS, 
implying that membrane collapse may not even be necessary for cGAS activation by 
micronuclei38. 
In ageing and in senescent cells, extranuclear chromatin fragments might enter the cytosol 
through nuclear envelope blebbing, loss of nuclear envelope integrity85,86 or even some 
nuclear export processes87. Among other characteristics, such as chromatin restructuring and 
altered metabolic activity, a hallmark of senescence is the senescence-associated secretory 
phenotype (SASP), characterized by secretion of various cytokines and chemokines that 
trigger a pro-inflammatory programme to clear senescent cells by the immune system88. 
Several studies have linked cytosolic chromatin and cGAS–STING to the regulation of 
SASP35,80,82. 
cGAS also detects cytosolic DNA arising from dysfunctional telomeres89,90,91. Precancerous 
cells escaping senescence-associated cell cycle arrest enter replicative crisis due to shortening, 
deprotection and fusion of telomeres. The resulting mitotic delay and problems with dicentric 
chromosomes lead to increased amounts of cytosolic chromatin and micronuclei that are 
detected by cGAS90. Extrachromosomal telomere repeat DNA — a hallmark of cancer cells, 
which is caused by activation of the alternative lengthening of telomeres (ALT) pathway — is 
also sensed by cGAS91. Consequently, the cGAS–STING pathway is found inactivated in ALT-
proficient tumour cells89. Importantly, as activation of the cGAS–STING axis can lead to 
autophagy (see below), further transformation of precancerous cells can be prevented by 
cGAS activation via induction of autophagy-dependent cell death90,91. Thus, activation of 
cGAS–STING signalling in precancerous and senescent cells, or in cells with mitotic problems, 
could be a mechanism to remove these cells, broadening the functional role of cGAS as an 
important sensor not only of pathogen-associated intracellular DNA but also of certain forms 
of endogenous aberrant and potentially pathological chromosomal states and genotoxic 
stress. 
It is so far puzzling why cGAS is suppressed when bound to the abundant nuclear chromatin, 
but activated by the interaction with chromatin fragments in micronuclei. Micronuclei contain 
marks for heterochromatin (trimethylated histone H3: H3K9me3 and H3K27me3) and DNA 
damage (γ-H2AX), suggesting that they are derived from transcriptionally silent regions of the 
genome and presumably feature DNA damage81,82, which could be associated with potent 
cGAS induction by micronuclear chromatin. Indeed, inactivation of DNA replication, repair and 
recombination genes, including RecQ-like helicase BLM (Bloom syndrome)83, RNase-H2 (ref.92) 
and the tumour suppressor BRCA2 (refs93,94), or increase of chromosomal damage by 
radiation, topoisomerase II95,96 or inhibitors of poly-ADP ribose polymerase 1 (PARP1; factor 
involved in DNA repair)97,98,99 leads to activation of the cGAS–STING pathway. Although cGAS–
STING activation associated with genome instability is currently attributed to formation of 
cytosolic micronuclei, mere co-compartmentalization of cGAS and micronuclear chromatin 
does not allow one to unequivocally infer that cGAS is activated by this aberrant chromatin. 
In fact, cGAS may not even require dsDNA to be activated. For instance, it was recently 
proposed that nuclear RNA–cDNA hybrid intermediates of LINE1 (long interspersed nuclear 
element 1) arising from RNase-H2 deficiency could account for cGAS–STING activation100. 
Thus, an important future direction is to investigate a possible activation of cGAS by damaged 
chromosomal DNA, and to address which specific ligands present in micronuclei, but absent 
from the nucleus, are responsible for the activation of cGAS specifically by micronuclear 
chromatin. 
 
Mechanism of cGAS activation 
Not all DNAs activate cGAS although they bind to cGAS. This is particularly true for most short 
DNA elements. Recent work suggests that DNA-induced dimer formation of cGAS by short 
DNAs is weak. Full activation and stabilization of active cGAS–DNA complexes proceeds by 
forming oligomeric structures or condensates and are strongly promoted by DNA beyond a 
certain length threshold that allows two or more cGAS molecules to bind to the same DNA. In 
the following, we discuss structural and mechanistic aspects of cGAS–DNA binding and 
catalysis, along with current models of cGAS clustering that help understand how cGAS could 
gain specificity towards infection-associated DNA. 
Oligomers, clustering and condensates 
All structures of active, DNA-bound cGAS obtained so far showed a dimer conformation. Here, 
binding of the two DNA molecules to the catalytic domain via sites A and B repositions lobe I 
relative to lobe II, enabling proper formation of the cGAS dimer with two sandwiched DNA 
molecules. Binding of DNA ligand also induces ordering in the activation loop, which is 
required for proper formation of ATP and GTP pockets and placement of catalytic residues 
(Fig. 3a). Although it is well established that DNA-mediated cGAS dimer formation is necessary 
to adopt a stable active state, the functional role of the peculiar cGAS dimer arrangement with 
two nearly parallel DNA ligands has remained unclear. 
The dimer structure suggests that ~16–18 bp of dsDNA should, in principle, be sufficient to 
fully activate cGAS. However, generic DNA <20 bp bound poorly to the cGAS catalytic domain 
and was capable of inducing cGAS catalytic activity in vitro only if cGAS was present at very 
high concentrations30,33. Short dsDNA substrates are likely not efficient in activating cGAS as 
they do not promote dimer formation at low cGAS concentrations. A notable exception are 
short dsDNA oligonucleotides contain G-rich ssDNA overhangs43. There are also species-
specific variations, with murine cGAS being more active towards shorter DNA than human 
cGAS, attributable to a species-specific variation in site A101. DNA <40 bp also fails to activate 
cGAS in human cells even at high concentrations32,42. In fact, the potency of DNA as a cGAS 
agonist increases with its length32,42,102. It is possible that a certain amount of DNA protruding 
from the core binding sites on the cGAS dimer is required for binding of the N-terminal 
domain, which helps stabilize cGAS dimerization33. However, the catalytic domain alone also 
displays this length dependency in vitro32, suggesting that activation of cGAS by DNA is 
strongly enhanced if the DNA is long enough to bind at least two cGAS catalytic domains. 
The DNA length-dependent activation of cGAS could be explained by the recent observation 
that cGAS dimers further assemble into oligomers, with unique biophysical properties of 
liquid-like droplets102, that could have important roles in regulating cGAS activation (Fig. 3). 
First insights into the formation of oligomeric assemblies of cGAS came from structural studies 
of cGAS with 39-bp DNA, showing that two cGAS dimers can assemble in a ‘ladder-like’ 
configuration, where they resemble ‘steps’ along the two DNA arms32(Fig. 3a,c). In this 
configuration, the nearby cGAS dimers can reinforce each other along the DNA by multivalent 
interactions, which was proposed to stabilize cGAS through cooperative effects as it will lead 
to high local cGAS concentrations. Subsequently, it was shown in cells that multivalent 
interactions involving the cGAS catalytic domain and the N-terminal domain lead to formation 
of liquid-like phase-separated condensates102 (Fig. 3c). In vivo, formation of such condensates 
was augmented by zinc102. Accordingly, negative-stain electron microscopy showed that the 
formation of the phase-separated structures requires a proper zinc-thumb dimerization 
element in cGAS, corresponding to a loop region that is stabilized through coordination of zinc 
and that forms a critical cGAS:cGAS dimer interface33. Interestingly, a third DNA binding site, 
termed site ‘C’, was recently identified and shown to promote mesh-like interactions or even 
formation of lattice-like structures in such condensates103 (Fig. 3a–c). The microstructures 
underlying the large condensates that can be visualized in cells need to be studied in more 
detail, but might include local cooperative, ‘nucleation’ elements, such as short ladders and 
lattice-like elements, in a macroscopically more amorphic and gel-like assembly as suggested 
by the electron microscopy data. Zinc ions, released through, for example, the ER and 
mitochondria, might help activate formation of these condensates through the zinc-thumb 
dimerization loop. Manganese was also found to increase cGAS activity, and accelerates the 
overall catalytic activity by an as yet unknown mechanism104,105, altogether suggesting that 
multiple divalent metals are necessary for optimal cGAS activation. 
Taking all data together, a unifying principle for cGAS catalytic activation emerges that could 
explain both cytosolic and nuclear functions of cGAS (Fig. 3c). In the absence of DNA, cGAS 
catalytic domains form a weak or transient dimer only. In a first step towards activation, cGAS 
binds DNA, but DNA binding per se does not yet trigger a catalytic active state. For instance, 
as discussed above, cGAS binds readily to short DNA, but short DNAs are generally poor 
activators of cGAS at low cGAS concentrations as they do not strongly promote dimer 
formation; nucleosome interactions might simply prevent dimer formation for other reasons, 
but detailed mechanisms await further structural analysis. Elements that support the 
formation of ladders32, DNA restructuring via DNA-bending proteins32, DNA interactions via 
site C103 and additional DNA-binding interactions through the N-terminal domain33 all 
comprise modes to potentially stabilize dimeric cGAS structures on DNA, leading to activation 
of cGAS that resembles an allosteric or cooperative switch, whereby formation of one cGAS 
dimer will enhance formation of additional cGAS dimers in its vicinity by condensating and 
prearranging DNA32,33. Multivalent interactions between assembled cGAS dimers and other 
DNA elements through, for example, site C and the N-terminal domain will promote formation 
of large, phase-separated condensates where cGAS and DNA are highly concentrated, strongly 
favouring the dimeric, active state of cGAS102. In the future, more mechanistic analyses of the 
structural nature and composition of condensates are necessary. Recent work suggests, for 
instance, that formation of cGAS–DNA condensates requires G3BP1 (a cofactor that enhances 
cGAS binding to dsDNA) and is promoted by RNA-dependent kinase PKR106. The latter is 
particularly interesting in light of the key role RNA plays in the formation of many other 
condensate structures. Finally, it needs to be investigated in more detail whether condensates 
are necessary for cGAS activation, whether condensate formation is required for cGAS 
activation and whether condensates have additional functions for cGAS activation apart from 
concentration of cGAS molecules and DNA. 
Two-stage catalysis 
Once switched into the active state, cGAS catalyses the generation of 2ʹ,3ʹ-cGAMP, which 
involves two distinct chemical reactions at the same catalytic site. In the first reaction, cGAS 
takes ATP and GTP as substrates and transfers ATP onto the 2ʹOH of GTP, generating the linear 
heterodinucleoside phosphate pppG(2ʹ–5ʹ)pA (ref.7). GTP and ATP are preferred substrates for 
this reaction over other ribonucleotides and they reinforce each other in a cooperative binding 
event88. However, cGAS products have been found to contain 10–20% linear 
homodinucleotides (pppG(2ʹ–5ʹ)pG and pppA(3ʹ–5ʹ)pA) in addition to the canonical 
intermediate pppG(2ʹ–5ʹ)pA, so side reactions occur at non-negligible rates7,107. Although 
linear homodinucleotides might, in principle, also occur in the cell, their conversion to cyclic 
homodinucleotides is negligible and these products presumably do not represent 
physiologically relevant species108. 
In the second step, the linear pppG(2ʹ–5ʹ)pA is taken as a substrate, and cGAS transfers the 
GTP moiety intramolecularly onto the 3ʹOH of the adenosine nucleoside phosphate. Hereby, 
adenine and guanine bind in the reversed order to the purine binding pockets; that is, the 
guanine of pppG(2ʹ–5ʹ)pA occupies the prior adenine binding site, and vice versa. The steric 
constraints imposed by binding of the linear intermediate and active site features are 
responsible for using the 2ʹOH in the first catalytic step and the 3ʹOH in the second. cGAS was 
engineered to produce 3ʹ,3ʹ-cGAMP using the bacterial homologue DncV as a structural guide 
for mutations around the active site, as DncV naturally produces 3ʹ,3ʹ-cGAMP (by using the 
3ʹOH rather than the 2ʹOH position of the acceptor nucleotide in the first reaction step that 
generates pppG(3ʹ–5ʹ)pA instead of pppG(2ʹ–5ʹ)pA)108. This engineering approach 
necessitated only few targeted mutations. In light of this finding and the fact the cGAS-related 
RNA sensors OASs also produce a 2ʹ–5ʹ linkage, it could be concluded that the formation of 
this specific linkage is an evolutionary adaptation in metazoans, allowing generation of 
metazoan-specific signalling molecules for the activation of immune responses. 
Kinetic dissection of the different reaction steps revealed that, during the two-step catalysis, 
a minority of the linear dinucleotides is directly converted to cGAMP without leaving the active 
site107 and a majority of the linear intermediates leaves the active site before the second 
reactions occurs. These linear products, once dissociated from the enzyme, probably cannot 
efficiently compete with the much higher concentrated ATP and GTP for the active site of 
cGAS. This would eventually lead to large accumulation of linear intermediates that could 
exceed cGAMP production, for which there is currently no evidence. It is possible that an 
unknown nuclease degrades these linear intermediates. However, an alternative or additional 
mechanism could be provided by the formation of cGAS oligomers and condensates. In such 
concentrated structures, linear intermediates will reach much higher local concentrations and 
thereby could much more efficiently compete with ATP and GTP; this would be further 
reinforced by reduced diffusion rates of the nucleotides into the condensates. At the same 
time, the condensates are associated with high concentrations of cGAS active sites, meaning 
that even if they dissociate, linear intermediates would easily encounter a cGAS active site 
nearby, which would foster efficient binding to cGAS and progression of the reaction. Finally, 
DNA at site C partially blocks the entry to the active site103 and could lower the dissociation 
rate of linear intermediates to favour cGAMP formation even further. Thus, cGAS–DNA 
condensates might act as a reaction chamber for more efficient cGAMP formation, whereas 
cGAS activated outside condensates could preferentially produce only linear intermediates 
that rapidly diffuse away from cGAS. Such a mechanism could effectively lower the ‘noise’ of 
the system, caused by possible low-level production of cGAMP by cGAS at chromatin or 
cytosolic DNA fragments under normal steady-state cell states. 
Regulation and modifications 
Although cGAS was initially identified as an interferon-stimulated gene27, its level of 
expression is largely constitutive in most cell types. As such, unlike for other PRR systems, the 
level of cGAS, and hence its activatability, is not regulated at the transcriptional level. Instead, 
numerous post-translational mechanisms have been shown to play an important role in 
regulating the activity of this receptor towards its ligand, its enzymatic activity or its half-life. 
cGAS is subject to different types of post-translational modifications, involving proteolysis, 
acetylation, glutamylation, ubiquitylation, sumoylation and phosphorylation (Table 2). Some 
modifications inhibit cGAS by directly modifying or cleaving at active site residues (Ser305 
(ref.109), Asp319 (ref.110) and Lys414 (refs111,112)), although it is somewhat unclear how the 
modifying/cleaving enzymes reach some of these residues in a folded cGAS. Several 
modifications are important in the context of nucleosomal interactions, dimer formation and 
condensation. Although site B and the loop involved in chromatin retention appear not to be 
regulated by the currently known set of modifications, site A and the dimer interface are 
subject to modifications by acetylation (Lys384 and Lys394 (ref.111)), sumoylation (Lys231 
(ref.113), Lys347, Lys384 and Lys394 (ref.114)) and ubiquitylation (Lys173 and Lys384 (ref.115)). 
These modifications might specifically prevent formation of active dimers and condensates 
(for example, via introducing electrostatic repulsion or inducing steric obstruction of dimer 
formation), but could still enable chromatin sequestration through site B. Similar effects are 
expected to result from cleavage of the N-terminal domain by caspase 1 in the context of 
apoptosis116. However, other regulatory means might exist as sumoylation target Lys479 
(ref.113) is not part of the known DNA binding or oligomerization interfaces. 
 
Functions of cGAS 
cGAS has a well-described catalytic function in producing the second messenger and STING 
activator cGAMP as detailed above. Recent work, however, showed that cGAS also possesses 
non-catalytic functions, in particular a non-catalytic function in inhibiting homologous 
recombination of DNA breaks in the nucleus. 
Catalytic functions 
The main catalytic function of cGAS is to produce cGAMP for the activation of STING3,4. 
Activation of STING then activates IRF3 and NF-κB to drive antiviral and pro-inflammatory 
immune responses; however, at the same time it also triggers effector functions that are 
independent of de novo gene expression (see below). cGAMP can trigger antiviral responses 
in bystander cells as well. It can diffuse through gap junctions to neighbour cells117 or enter 
distant cells through incorporation into viral capsids118 (Fig. 2). Some cGAMP can be released 
into the microenvironment (for example, upon cell damage or necrotic cell death) and this 
extracellular cGAMP can enter other cells, most likely via channel-dependent mechanisms. For 
example, a transmembrane transporter, SLC19A1, has been found to serve as a direct 
importer for cGAMP119,120. Of note, extracellular cGAMP is degraded by a specific mammalian 
phosphodiesterase, ENPP1 (ref.121), thereby controlling cGAMP direct uptake by cells. A host-
encoded, intracellular phosphodiesterase degrading cGAMP has not yet been identified and 
the metabolic fate of cGAMP inside cells is still unclear. In any case, taking into account the 
intercellular transmission of both cGAMP and cGAS DNA substrates discussed above, catalytic 
function of cGAS has local, microenvironmental and perhaps even more systemic roles to elicit 
defence mechanisms by activating STING (see next section) and its downstream pathways 
leading to interferon expression or cell death. 
Non-catalytic functions 
In addition to its primary catalytic function, cGAS also has been found to possess various non-
catalytic functions. For instance, cGAS was observed to promote sensing of extracellular cyclic 
dinucleotides, which enter the cell through endocytosis or importers. Interestingly, these 
extracellular cyclic dinucleotides enhance the formation of the catalytic active, dimeric form 
of cGAS122, suggesting that they might be able to shift the equilibrium towards cGAS dimers, 
thereby facilitating cGAS activation. 
In the nucleus, cGAS has been found to inhibit the repair of DNA double-strand breaks by 
homologous recombination in a mechanism that neither requires STING nor catalytic activity 
of cGAS37,38 (Fig. 2). In homologous recombination, the DNA ends are resected to 3ʹ single-
strand tails, onto which the RAD51 recombinase is loaded in a BRCA2-dependent manner 
(reviewed previously123). RAD51 catalyses strand pairing with the homologous template, 
where the broken strand is extended by DNA synthesis. A first study showed that DNA damage 
increases nuclear localization of cGAS, which occurs by active cGAS import primed by 
dephosphorylation of Tyr215 (ref.37) (Table 2) (a site phosphorylated by B-lymphoid tyrosine 
kinase (BLK) to facilitate cytosolic retention). Tyr215 is located in a DNA binding site of cGAS 
and the phosphomimetic Tyr215Glu mutation reduces DNA binding, suggesting that 
dephosphorylated Tyr215 is necessary for nuclear cGAS functions by allowing its proper 
interactions with DNA38. cGAS was found at sites of chromosomal damage marked by PARP1 
and γ-H2AX, where it interacted with γ-H2AX and poly-ADP ribose (PAR)37 (but these 
interactions are not sufficient to recruit cGAS to strand breaks independently from DNA 
binding)38. At these sites, cGAS perturbed formation of the PARP1–TIMELESS complex that is 
involved in homologous recombination. However, subsequent work suggested an even more 
direct inhibitory function of cGAS on homologous recombination. Here, cGAS formed 
oligomeric clusters with the homologous dsDNA template and prevented pairing of RAD51–
DNA filaments and strand invasion of the broken DNA strand into the homologous strand38. 
As cGAS was found to be chromatin-associated throughout the cell cycle40, inhibition of 
homologous recombination is not simply an effect of nuclear import upon damage, as initially 
proposed37, but likely involves relocalization of chromatin-bound cGAS to sites of 
recombination where it competes with RAD51 for DNA. Competitive interplay between 
proteins at recombination intermediates (RAD51, replication protein A (RPA)) and cGAS had 
been found before the role of cGAS in homologous recombination was revealed, and RAD51 
and RPA were suggested to sequester DNA fragments resulting from DNA damage and repair 
in the nucleus in order to prevent cGAS activation124. However, ssDNA — the substrate for 
RPA and RAD51 — does not activate cGAS in vitro, so the nature of activating nucleic acids for 
cGAS in the context of DNA damage needs further study. 
Interestingly, cGAS has little effect on the non-homologous end-joining (reviewed 
previously123) DNA repair pathway37,38, which is executed through a different chromatin 
structure than homologous recombination, does not involve homology search and occurs with 
a smaller amount of free dsDNA on a DNA template. Thus, it is possible that simply the 
presence of sufficiently long accessible dsDNA is enough to enable high-affinity binding of 
cGAS oligomers to DNA and subsequent activity. 
In the future, it will be interesting to investigate the biology of cGAS activity in DNA repair in 
more detail. This function could simply represent a tolerated by-product of nuclear 
sequestration of cGAS. Nevertheless, it could also have a more active role. For instance, it was 
shown that knockdown of cGAS suppresses DNA damage and inhibits tumour growth both in 
vitro and in vivo37, suggesting cGAS as an antitumour factor. An important clue to resolving 
this question could be specific recruitment of cGAS to sites of damage, but this is still 
controversial. Another important question is whether cGAS is active while at homologous 
recombination sites. If this was the case, this could, for instance, trigger defensive 
programmes to help eliminate cells with DNA breaks. Finally, the role of cGAS in sequestering 
exposed dsDNA from the DNA repair machinery could also be a function that has evolved to 
detect and interfere with DNA virus replication in the nucleus, which often proceeds by 
engaging host DNA damage response and repair factors125. Finally, although there is currently 
no evidence that formation of larger, phase-separated condensates plays a role in nuclear 
functions of cGAS as seen in the cytoplasm, the ability to self-oligomerize is necessary for 
inhibition of homologous recombination38. Thus, perhaps a related clustering mechanism of 
cGAS is important for its nuclear functions as well, but on a different scale (involving smaller 
or less stable condensates). 
 
STING activation and signalling 
STING activation by binding of cGAMP and subsequent signal transduction is best understood 
for its capacity to trigger IRF3 phosphorylation, which drives the expression of a plethora of 
antiviral genes. Notably, we came to appreciate that, in fact, this best-studied role in IRF3 
activation represents the most recent evolutionary step in STING downstream signalling, and 
that STING also carries out additional, evolutionarily more ancient functions, which can be 
mechanistically and functionally separated from IRF3 activation. In the following, we briefly 
discuss four independent STING functions: IRF3 activation, NF-κB activation, autophagy 
regulation and induction of lysosomal cell death (LCD) via STING lysosomal trafficking. 
Structural mechanisms of STING and subsequent IRF3 activation 
Recent cryo-electron microscopy studies revealed the structure and domain organization of 
full-length chicken and human STING126 and — at low resolution — its complex with TBK1 
(ref.127). STING spans the ER membrane four times with its N-terminal portion. Both the C-
terminal part of STING that contains the ligand binding domain (LBD) and the C-terminal tail 
(CTT) face the cytosol (Fig. 4a). Under steady-state conditions, ER-bound STING forms a dimer 
so that their LBDs generate a V-shaped ligand binding pocket for one cyclic dinucleotide ligand, 
as previously revealed by crystallographic studies6,128,129,130,131. In this dimer, the 
transmembrane helices of the two STING molecules are arranged so that they form an 
integrated, domain-swapped architecture (Fig. 4a,b). A connector helix tethers the last 
transmembrane helix of STING with its LBD. The two connector helices of one STING dimer 
form a right-handed crossover, which results in close intermolecular interactions at the 
junction (Fig. 4b). The CTT of STING contains a highly conserved TBK1-binding motif127,132 that 
is directly adjacent to a pLxIS motif, which is important for IRF3 activation133,134 (Fig. 4c). 
Binding and imaging studies suggest that a considerable amount of TBK1 is already present on 
these preformed, inactive STING dimers on the ER127. However, despite two TBK1 molecules 
being bound in close proximity on one STING dimer, TBK1 perhaps does not become activated 
when bound to STING dimers as sterical hindrance prevents phosphorylation in trans. Upon 
cGAMP binding, the STING dimer undergoes a conformational switch, which results in a 180° 
clockwise rotation of its LBDs in relation to the transmembrane portion (Fig. 4b). This rotation 
relieves the right-handed crossover of the connector helices and also allows the closure of a 
lid structure around cGAMP. Associated with this conformational switch, α-helices 2 and 3 of 
the LBD (LBDα2 and LBDα3) tilt downwards, which is suggested to generate a surface 
geometry that promotes the lateral oligomerization of several STING molecules in a side-by-
side configuration (Fig. 4d). This oligomerization constitutes an important prerequisite for 
STING gaining its signalling competence and — similar to cGAS oligomerization/condensation 
— has cooperative/switch-like properties. Oligomerization was found to be promoted by 
disulfide bond formation of Cys148 in the connector helix (Fig. 4b), suggesting that STING 
activation could be nearly irreversible. 
STING variants with mutations in the oligomerization interface are not only incapable of 
activating TBK1 (see below) but are also unable to exit the ER, suggesting that oligomerization 
dictates translocation to the Golgi compartment126,135. At the same time, ligand binding also 
seems to make the CTT of STING better accessible to TBK1 — the STING oligomer formation 
positions ‘cis’ TBK1 molecules in close proximity to ‘trans’ TBK1 molecules of the adjacent 
dimer, in a way that the activation loop of the ‘trans’ TBK1 molecules is accessible to the 
catalytic centre of the kinase domain of the ‘cis’ molecule. This allows TBK1 to in trans 
phosphorylate and activate TBK1 molecules in close proximity (Fig. 4d). Active TBK1 then 
exerts catalytic activity towards the critical serine residue within the pLxIS motif134 (Ser366) of 
the CTT (Fig. 4d). Current structural data imply that TBK1 is only able to phosphorylate the CTT 
of STING of an adjacent STING dimer, rather than the CTTs of its own dimer. Upon 
phosphorylation, this motif serves as a docking site for IRF3, which is then brought into close 
proximity to the catalytically active TBK1 molecules126,132. 
As mentioned above, STING exits the ER towards the Golgi already upon oligomerization (Figs 
4d,5). This process depends on canonical COPII coat complex-dependent anterograde 
transport136, but it remains unclear what signal within STING is sensed to initiate this 
transport. STING travels via the ER–Golgi intermediate compartment (ERGIC) to the Golgi. 
Studies employing pharmacological inhibitors or microbial effector proteins suggest that 
STING activates IRF3 as early as the ERGIC137. In fact, blocking ER exit of STING by 
pharmacological means completely abolishes IRF3 activation. These results would suggest 
that STING oligomer formation is either linked to ER exit or that additional factors beyond 
oligomer formation are required for IRF3 activation that are only met at the ERGIC. Indeed, 
another interesting feature of STING activation is the fact that palmitoylation at cysteine 
residues close to transmembrane domain 3 is required to activate STING138,139. It was shown 
that palmitoylation facilitates STING cluster formation at the Golgi, which is required for 
maximal signal transduction. However, preventing or blocking palmitoylation does not 
interfere with the exit of STING from the ER. This would suggest that palmitoylation does not 
impact on structurally determined side-by-side oligomerization of STING that is induced by 
the conformational switch upon ligand binding. To this end, the exact nature of the 
palmitoylation-induced STING cluster formation and its role in signal transduction remains to 
be clarified. It should be noted that numerous additional post-translational modifications 
(Table 2), as well as interactions with modulatory proteins (Table 1), have been described to 
modulate various steps in STING-dependent signal transduction. For example, different types 
of ubiquitylation have been shown to facilitate its interaction with TBK1 or to impact on its 
half-life (Table 2). With new structural insight into the activation of STING and its interaction 
with TBK1, it will be worthwhile to address the molecular impact and epistatic relationship of 
these modifications to the individual steps of STING activation. 
NF-κB and MAPK pathway activation by STING 
Human and murine STING activation also triggers NF-κB and MAPK pathway activation, albeit 
to a lower extent compared with other PRR cascades140. In fact, unlike other PRR systems that 
assemble TRAF (tumour necrosis factor receptor-associated factor)-dependent signalosomes 
to recruit the TAK (transforming growth factor-β-activated kinase) and the IKK (inhibitor of NF-
κB kinase) complex to activate MAPK and NF-κB, respectively, mammalian STING appears to 
employ an unconventional signalling route to the activation of these transcription factors (Fig. 
5b). The exact mechanisms of STING-dependent NF-κB and MAPK activation remain 
unresolved, in that conflicting models have been proposed. On the one hand, it has been 
shown that TBK1 functions upstream of NF-κB activation141,142. On the other hand, evidence 
has been provided that the CTT is not required for this function140,143, which would also rule 
out a role for TBK1. The latter model would be in line with studies on fly STING that lacks the 
CTT. Here, the immune deficiency signal transduction pathway that is orthologous to the 
vertebrate NF-κB cascade is triggered upon STING activation despite the absence of a 
CTT144,145. Hence, it is possible that STING-dependent NF-κB activation is governed by a signal 
from within the LBD of oligomerized STING. Interestingly, ray-finned fish have evolved a C-
terminal extension of the STING CTT, which serves to recruit TRAF6 (ref.140). This additional 
module results in a far stronger NF-κB activation as compared with mammalian STING species. 
Finally, it has been observed that STING can result in NF-κB activation downstream of DNA 
damage signalling independently of cGAS. This response was shown to assemble an 
unconventional STING signalling complex, resulting in TRAF6-dependent NF-κB activation146. 
How STING activates the MAPK pathway remains to be elucidated. 
STING-triggered autophagy 
As outlined above, two modules within the STING CTT are critically required to activate IRF3: 
the TBK1-binding motif is important for TBK1 recruitment and activation, whereas the pLxIS 
motif — upon phosphorylation by TBK1 — recruits IRF3 for its subsequent phosphorylation134. 
Interestingly, these modules within the CTT evolved only in the vertebrate lineage, alongside 
the type I interferon system18, raising the question of the function of STING in these non-
vertebrate species. In fact, one important STING-dependent signalling output is autophagy147, 
which operates independently of its CTT and, as such, in the absence of TBK1 and IRF3 
activation136. At the same time, blocking IKK activation does not impair autophagy136. Upon ER 
exit, STING triggers autophagy from the ERGIC, as seen by LC3 (also known as microtubule-
associated proteins 1A/1B light chain 3B) lipidation and autophagosome formation (Fig. 4c). 
The canonical autophagy pathway is initiated by the activation of the Unc-51-like kinase 1 
(ULK1) complex that activates components of the class III PI3K (PI3KC3) complex I by 
phosphorylation. This complex then triggers the local formation of phosphatidylinositol 3-
phosphate (PtdIns3P) residues, forming the so-called phagophore. These residues serve as 
docking sites for PtdIns3P effector proteins that then recruit and activate the ubiquitin-like 
conjugation machineries that lead to the growth and functionalization of autophagic 
membranes148. In the context of STING, the canonical autophagy initiation machinery (ULK1 
and PI3KC3 complexes) is not involved in STING-dependent autophagy, but further 
downstream components, such as the PtdIns3P effector protein WIPI2 and ATG5, are 
shared136. Clear mechanistic insight into the contribution of STING to autophagy initiation is 
missing, yet a conserved motif located in STING’s LBDα4 seems to be important for this 
function. Induction of autophagy has also been reported for STING from the sea anemone, 
which lacks the CTT, indicating that autophagy appears to be an ancient, possibly primordial, 
function of STING. In line with these observations, fly STING, which also lacks the CTT, still 
functions to restrict microbial pathogens. Although this relies on transcriptional responses 
downstream of the immune deficiency pathway144,145 (see above), autophagy induction has 
also been shown to be of importance149. Also, in mammals, STING-dependent autophagy has 
been shown to play a protective role in the clearance of microbial pathogens such as 
Mycobacterium tuberculosis147, certain Gram-positive bacteria150 and also herpes simplex 
virus 1 infection151. Intriguingly, in the context of herpes simplex virus 1 infection, autophagy 
but not type I interferon induction seems to constitute the prime effector function of STING 
in controlling viral infection151. 
STING trafficking to the lysosome and cell death induction 
STING activation can trigger cell death in various ways. As such, along with its IRF3-dependent 
induction of antiviral genes, STING induces the expression of numerous pro-apoptotic and pro-
necroptotic molecules that facilitate respective programmed cell death pathways (reviewed 
previously152). Moreover, in certain cell types, STING engagement can also induce LCD, a lytic 
cell death programme (primarily characterized in human myeloid cells), which operates 
independently of classical programmed cell death pathways. This functionality was found to 
require translocation of STING to the lysosome153. Here, lysosomal STING accumulation 
triggers lysosomal membrane permeabilization, the subsequent release of lysosomal 
hydrolases and, thereby, cell death153 (Fig. 5d). It is possible that this type of cell death is at 
play in cells from patients with SAVI (STING-associated vasculopathy with onset in infancy), 
who harbour gain-of-function mutations in the STING1 gene154. In these patients, a 
constitutively active STING molecule triggers continuous antiviral gene expression, but also 
cell-intrinsic death of lymphocytes and myeloid cells. Indeed, in murine models of SAVI, a large 
part of disease progression and cell death occurs independently of IRF3 and antiviral gene 
expression155,156,157. In myeloid cells that succumb to STING-induced LCD, a secondary 
inflammatory response is triggered through the activation of the NLRP3 inflammasome 
mediated by the loss of plasma membrane integrity and cellular K+ efflux, followed by the 
release of inflammatory cytokines by the dying cell. This pathway constitutes a general, non-
specific response pattern of myeloid cells that is activated upon membrane perturbation158. 
Of note, this NLRP3-dependent inflammatory response has not evolved to specifically detect 
cell death downstream of STING and is also not operational in primordial organisms. However, 
it is conceivable that STING-induced LCD and associated secondary inflammation in general 
constitutes a ‘last resort’ response pattern that functions to prevent microbial propagation, 
as it has been ascribed to autophagy. Yet, to substantiate this concept, it would be important 
to study systems in which autophagy can be dissected from LCD. In cells that do not succumb 
to LCD, an alternative outcome of trafficking STING to the lysosome is its lysosomal 
degradation153,159. Indeed, the half-life of STING is largely controlled by the lysosomal 
machinery, rather than by proteasomal degradation or autophagy136,159. A functional 
consequence of lysosomal degradation of STING is a shutdown of its signalling. Consequently, 
preventing lysosomal trafficking or lysosomal activity results in augmented STING levels and 
also increased antiviral gene expression136,159. Imaging studies suggest that STING translocates 
to the lysosome after exiting the Golgi through the late endosome route136,159, although 
specific determinants of this transport mechanism remain unclear. As for ER export in general 
(see above), STING translocation to the lysosome occurs independently of TBK1 and its CTT 
being phosphorylated. Two conserved regions within the LBDα3 have been implied in dictating 
translocation of STING to the lysosome159, yet additional studies are required to explore the 
underlying mechanism. 
 
Conclusions and perspectives 
The mechanism of intracellular DNA detection has remained one of the most enigmatic fields 
in innate immunity. With the discovery of the cGAS–STING axis, we now have a good 
understanding of what the underlying components are and how they sense pathogens. 
However, it is now becoming more and more clear that the cGAS–STING axis also responds to 
a wide range of endogenous nucleic acids implicated in cellular stress and damage, and that 
its signalling outputs reach far beyond IRF3 activation. Moreover, cGAS appears 
predominantly as a nuclear protein in steady state with additional non-catalytic functions, 
raising the question of how cGAS is able to discriminate self from non-self or harmless from 
dangerous, respectively. Recent data provided a new perspective that robust cGAS activation 
occurs in oligomers or even may require higher-order assemblies in the form of liquid-like 
phase-separated condensates. These insights have challenged the conventional picture of 
cGAS functioning as a cytosolic sensor for DNA with a simple ligand to receptor stoichiometry, 
but more work is needed to fully understand the role and composition of the condensate 
structures. Similarly, active STING oligomerizes to serve as a platform for subsequent signal 
transduction and its signalling capacity goes beyond the activation of IRF3. Such 
oligomerization and clustering-based mechanisms could ensure a cooperative ‘switch-like’ 
response of signalling as a function of increasing concentrations of agonistic ligand, with a high 
signal-to-noise response and specificity towards DNA that allows clustering, such as long DNA. 
On the level of cGAS–DNA interactions, we still do not understand the differences between 
the binding of cGAS to different ligands. One interesting aspect to study here is how cGAS 
interacts with different types of chromatin, in particular whether cGAMP is produced by 
nuclear cGAS and under which circumstances, and what features make chromatin in 
micronuclei a cGAS agonist. Furthermore, although certain hypotheses have been put forward 
regarding the mechanism of distinguishing self from non-self/damage by cGAS, including 
subcellular compartmentalization of cGAS, the mechanisms involved in this process remain 
elusive. Here, new insights could potentially be obtained through better understanding of the 
structural nature and composition of condensates and the role of the N-terminal domain in 
macromolecular interactions, which has eluded more detailed analyses owing to its 
unstructured nature. Finally, we also lack an organismic and evolutionary perspective of the 
‘non-canonical’ — beyond cGAMP production and induction of interferon signalling — 
functions of cGAS–STING and whether they serve important physiological roles. These new 
findings could spur the generation of novel strategies to modulate cGAS–STING that go 
beyond targeting of the catalytic function of cGAS or the ligand binding pocket of STING, which 
could be used to either stimulate or inhibit cGAS–STING in the context of various pathologies, 
including cancer and diseases driven by pathologic inflammation (Box 2). In the context of 
cancer, it would be particularly interesting to study the role of cGAS as a blocker of DNA repair 
via homologous recombination, which could potentially fuel cancer-associated genomic 
alterations or, on the contrary, lead to deleterious loss of genomic integrity and cancer cell 
death160. It will also be of interest to further illuminate the role of STING in autophagy 
induction, which, similarly to DNA repair suppression, has dual roles in cancer148. At the same 
time, further studies should address the mechanisms and regulation of STING targeting the 
lysosome, understanding of which could give further control over cGAS–STING signalling (by 
switching it off) or could be used for the induction of LCD. 
  
Box 1 -  Non-self recognition by the innate immune system 
The conceptual framework for how the innate immune system detects the presence of non-
self is based on the pioneering work by Janeway177. Here, it was postulated and later 
experimentally validated that the host has evolved so-called pattern recognition receptors 
(PRRs) to sense the presence of pathogen-derived molecular patterns (PAMPs) as non-self. 
PAMPs are considered invariant molecules that are important for the microbial life cycle and 
specific to the microbial pathogen, but not present within the host. However, subsequent 
studies have shown that various PRRs can also be activated by endogenous, host-derived 
molecules under conditions of cell or tissue damage. In analogy to the PAMP terminology, 
these molecules are typically referred to as damage-associated molecular patterns 
(DAMPs)178. DAMPs can be formed or released in the context of microorganism-inflicted 
damage, and thereby indirectly alert the host to microbial infection. At the same time, DAMPs 
can also be generated under non-infectious damage, thus contributing to acute or chronic 
sterile inflammatory conditions. Which molecules act as DAMPs and what is the molecular 
basis of their detection by PRRs? On the one hand, it has been shown that endogenous 
molecules can be rendered agonistic for PRRs by certain damage-associated modifications (for 
example, oxidized lipids). On the other hand, DAMPs can also constitute unmodified self-
molecules that pass a certain concentration threshold or gain access to certain PRRs that are 
usually shielded away from these molecules under steady-state conditions. Especially, host-
derived nucleic acids are found in the latter category179. Endogenous nucleic acids are typically 
indistinguishable from microbial nucleic acids and, as such, respective PRRs are often 
positioned into compartments that are devoid of potential self-ligands. For example, Toll-like 
receptor 9 (TLR9) is located within the endolysosomal compartment to avoid the detection of 
extracellular self-DNA. Indeed, relocalizing this receptor to the cell surface results in a fatal 
autoinflammatory disease. Analogous to TLR9, it has been suggested that the positioning of 
cyclic GMP–AMP synthase (cGAS) within the cytoplasm functions to avoid self-DNA, which is 
abundantly present within mitochondria and the nucleus, but not the cytoplasm. However, 
more recent data (as discussed in this article) indicate that this model is too simplistic. Indeed, 
accumulating evidence suggests that cGAS is also present in the nucleus. Here, additional 
safeguard mechanisms ensure that recognition of nuclear self-DNA does not occur. These 
mechanisms seem to operate at the level of ligand availability, as well as regulation of the 
catalytic activity of cGAS by certain nuclear factors, but the underlying mechanisms have not 
been resolved. 
 
Box 2 - cGAS–STING signalling in disease and therapy 
Cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) is primarily involved 
in the response to microbial infection. Hence, activation of this signalling pathway could be 
explored as a viable strategy to combat infections, in particular as several viral pathogens are 
able to circumvent activation of cGAS–STING signalling180. However, as described throughout 
the main text, beyond recognition of pathogens, cGAS–STING also mounts an inflammatory 
response to certain self-DNA molecules, and, thus, regulation of this pathway could be a viable 
strategy to modulate sterile inflammation for therapeutic benefit. There are two primary 
disease scenarios that could benefit from modulation: activation or inhibition of cGAS–STING, 
namely cancer and diseases with pathogenesis attributed to increased inflammatory 
responses. In the following, we briefly outline these scenarios. For a detailed overview, please 
refer to two other review articles181,182. 
The first indications for STING agonism exerting therapeutic effects in cancer stem from 
studies predating the discovery of this signalling cascade. The two tricyclic compounds DMXAA 
(5,6-dimethylxanthenone 4-acetic acid)183 and CMA (10-carboxymethyl-9-acridanone)184 were 
identified as molecules that exerted potent antitumour and antiviral activity, respectively. 
Later, it turned out that both these compounds serve as direct STING agonists. However, these 
compounds only activate rodent, but not human, STING185,186, explaining the failure of DMXAA 
in clinical trials for cancer therapy187. Nevertheless, in line with the promising preclinical data 
on DMXAA in mouse models, STING agonism using cyclic GMP–AMP (cGAMP) or stabilized 
derivatives thereof was tested and found to be efficacious in various murine cancer 
models67,188,189,190. The beneficial role of cGAS–STING signalling was furthermore supported 
by the notion that spontaneous or treatment-associated antitumour responses were 
enhanced or facilitated by the engagement of cGAS–STING signalling, even in the absence of 
exogenous agonists16,67,190,191. Moreover, activation of cGAS–STING by cancer-associated 
agonistic DNA in transformed, senescent cells is important for their immune clearance in 
mice82, and suppression of cGAS–STING activation has been observed in several cancers and 
cancer cell lines, including those that are telomerase negative and rely on the alternative 
lengthening of telomeres pathway89. Next to the protective role of the cGAS–STING axis in 
cancer, there are some reports on the pro-tumorigenic or pro-metastatic activity of STING 
agonism192,193,194. Nevertheless, STING agonism is being currently pursued as a therapy in 
various immuno-oncology settings195. 
A lot of sterile inflammatory conditions are triggered or perpetuated by inadvertent activation 
of pattern recognition receptors through the endogenous damage-associated molecular 
patterns. Given that cGAS cannot discriminate self from non-self DNA at the structural level, 
avoidance of self-DNA recognition needs to be counteracted by several means. Among others, 
cellular segregation of cGAS away from its ligand via compartmentalization of activatable cGAS 
to the cytosol and the plasma membrane, the sequestration of cGAS in the inactive form in 
the nucleus as well as the activity of DNA degrading enzymes that keep potential self-DNA 
substrates that enter the cytoplasm below a certain threshold seem to play key roles179. 
However, if these mechanisms are breached or overwhelmed by the abundant supply of self-
DNA, for example in the context of persistent or increased DNA damage or cell death, cGAS–
STING signalling can be potently activated. For example, loss of function mutations in the 
endolysosomal DNA endonuclease DNase II or the cytosolic DNA exonuclease TREX1, as 
observed in patients with Aicardi–Goutières syndrome, result in overactivation of cGAS–STING 
signalling due to increased availability of the DNA ligand12,13,14,15. As a consequence, 
constitutive STING activation and associated effector functions, such as type I interferon 
production, can result in cell or tissue damage. These disease entities are commonly referred 
to as type I interferonopathies196, which also encompass diseases with other, related 
pathomechanisms. A similar scenario is observed for gain-of-function mutations in STING, as 
documented in patients with SAVI (STING-associated vasculopathy with onset in infancy), 
which result in a ligand-independent activation of its signalling154. Heterozygous mutations in 
TREX1 lead to less severe and heterogeneous phenotypes, such as systemic lupus 
erythematosus197 or familial chilblain lupus erythematosus198. At the same time, a sizeable 
proportion of patients with systemic lupus erythematosus (15%) display increased cGAMP 
levels despite carrying wild-type alleles for TREX1 (ref.199). This argues for an as yet unknown 
or polygenic cause of systemic lupus erythematosus involving the cGAS–STING axis. At the 
same time, aberrant activation of STING signalling has been implied in diverse chronic disease 
settings, such as macular degeneration200, non-alcoholic steatohepatitis201 or Parkinson 
disease202. Moreover, acute tissue damage, as seen in the context of myocardial infarction, 
has been shown to involve cGAS–STING activation with adverse outcomes203. Based on these 
considerations, efforts are being undertaken to develop compounds that antagonize the 
cGAS–STING signalling cascade at various levels: DNA binding of cGAS, catalytic activity of 
cGAS, cGAMP binding to STING and the use of allosteric modulators of STING, such as 
inhibitors of palmitoylation204. 
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Fig. 1: Overview of canonical cGAS–STING signalling. 
Cyclic GMP–AMP synthase (cGAS) consists of a two-lobed catalytic domain and an extended 
amino-terminal (N-terminal) domain. It recognizes and is activated by DNA ligands 
(canonically single-stranded or double-stranded molecules longer than 40 bp) and assembles 
into a dimer, in which both cGAS protomers are bound to their own DNA ligand, with the DNA 
strands sandwiched between the two cGAS protomers. Each protomer has two principal DNA 
binding sites, A and B. In the dimer, the DNA molecules are bound to site A of one cGAS 
protomer and to site B of the respective other protomer. The crystal structure of this 
arrangement is shown in the right-hand box (PDB ID 6CTA). DNA binding sites A and B are 
annotated in this structure. This dimerization is required for cGAS to acquire a stable active 
conformation. Active cGAS produces the cyclic dinucleotide 2ʹ,3ʹ-cyclic GMP–AMP (2ʹ,3ʹ-
cGAMP). The box on the right-hand side shows cGAMP as a stick model with green carbon 
atoms, blue nitrogen atoms, red oxygen atoms and white phosphorus atoms (PDB ID 4KSY). 
cGAMP binds to stimulator of interferon genes (STING), leading to TANK-binding kinase 1 
(TBK1)-dependent phosphorylation (P) of interferon regulatory factor 3 (IRF3). The active IRF3 
dimer translocates to the nucleus and activates transcription of type I interferon genes. cGAS–
STING signalling leads also to the expression of genes for pro-inflammatory cytokines through 
NF-κB (dashed lines). Left insets list the main sources of DNA serving as cGAS ligands, 
downstream pathways of cGAS–STING signalling and implications of cGAS–STING signalling in 
diseases. ER, endoplasmic reticulum. 
 
Fig. 2: Cellular localization and DNA ligands of cGAS. 
Cyclic GMP–AMP synthase (cGAS) is found in the cytosol where it encounters its agonist DNA 
substrates (highlighted in red), mostly comprising long DNAs. However, other DNAs, including 
Y-form DNA (comprising a double-stranded DNA (dsDNA)–single-stranded DNA junction) from 
retroviruses are also able to activate cGAS. Agonistic DNA can be derived from a plethora of 
sources (shown in blue boxes), including exogenous sources (DNA viruses, retroviruses, 
intracellular bacteria) and endogenous sources (stressed mitochondria, which release 
mitochondrial DNA (mtDNA) and chromatin fragments in the cytosol and micronuclei resulting 
from mitotic or replicative crises and DNA damage). A prominent pool of cGAS is sequestered 
at the plasma membrane via binding to phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) 
on the inner plasma membrane leaflet. This sequestration could help keep cGAS away from 
endogenous DNA, at the same time allowing cGAS to detect more rapidly or efficiently DNA 
from viruses entering the cell (dashed arrows). In steady state, cGAS is also sequestered in the 
nucleus by binding to chromatin. Chromatin-bound cGAS is inactive. Nevertheless, it has been 
reported for HIV-2 that its DNA sensing by cGAS occurs in the nucleus, raising the possibility 
of nuclear sensing of viruses by cGAS. After binding its agonist DNA, cGAS is activated, which 
leads to enzymatic production of 2ʹ,3ʹ-cyclic GMP–AMP (2ʹ,3ʹ-cGAMP), which activates 
stimulator of interferon genes (STING) downstream signalling (Fig. 5). cGAMP can also be 
released to the extracellular space, for example by dying cells, where it can be degraded by 
phosphodiesterases, such as ENPP1. Nevertheless, some extracellular cGAMP can also enter 
other cells in the microenvironment either via endocytosis or uptake via transporters, such as 
SLC19A1, inducing paracrine signalling. Finally, cGAMP can spread to bystander cells via gap 
junctions or by being incorporated into viral capsids. In addition to its role in activating STING, 
nuclear cGAS has also been implicated in inhibiting DNA repair via homologous recombination, 
but how certain types of DNA damage induce activation of cGAS, whereas non-damaged 
chromatin does not, remains to be established. ecDNA, extrachromosomal DNA; ER, 
endoplasmic reticulum; IL-1R, interleukin-1 receptor. MIMP, mitochondrial inner membrane 
permeabilization; MOMP, mitochondrial outer membrane permeabilization. 
 
Fig. 3: Mechanism of cGAS activation. 
a) Structure of ligand-free (apo) human cyclic GMP–AMP synthase (cGAS) (in ‘side’ view, PDB 
ID 4KM5) (left). DNA-bound cGAS dimer in the active conformation (PDB ID 6CTA). DNA 
binding and dimer formation activate cGAS by ordering of an active site activation loop and 
closure of the active site channel. Of note, the amino-terminal (N-terminal) domain (indicated 
on apo cGAS) has not yet been resolved in any structure (middle). Oligomeric states showing 
how binding to longer DNA in a ladder configuration (PDB ID 5N6I) and DNA binding at the 
newly discovered site C (PDB ID 6EDB) can lead to reinforced dimers and more condensed 
structures (right; see part c for cartoon models). b)  ‘Front’ view of cGAS showing the three 
DNA binding sites A, B and C (PDB ID 6EDB). C) Model for the allosteric/cooperative activation 
of cGAS by clustering. Binding of cGAS to non-agonistic (short) DNA does not robustly lead to 
formation of an active dimer state. cGAS also binds to nucleosomes, which does not lead to 
an active state but inactive cGAS sequestration; the mode of binding of cGAS to chromatin is 
as yet unknown. In the presence of longer DNA, however, different means of clustering 
oligomerization and arrangement of DNA (formation of ladder-like structures of cGAS dimers 
along DNA, interaction with DNA via N-terminal charged patches, mesh-like interactions with 
DNA via site C, DNA shaping via DNA-bending proteins) lead to more stable, active dimer 
structures and promote the formation of large liquid–liquid phase-separated condensates. In 
these condensates, cGAS is highly concentrated, which likely further stabilizes the active 
dimeric state and promotes its catalytic activity. 
 
Fig. 4: Mechanism of STING activation. 
a) Cartoon of the membrane-bound stimulator of interferon genes (STING) dimer with 
annotated structural domains and elements. B) Cryo-electron microscopy structure of the 
ligand-free chicken STING dimer (left, PDB ID 6NT6) and the 2ʹ,3ʹ-cyclic GMP–AMP (cGAMP)-
bound STING dimer (PDB ID 6NT7). 2ʹ,3ʹ-cGAMP binding results in closing of the lid elements 
and a rotation of the ligand-binding domains (LBDs) with respect to the transmembrane 
domains (each formed by four transmembrane helices 1–4), generating a surface geometry 
for oligomerization. Cys148 of human STING (green stars) is implicated in disulfide bond 
formation that stabilizes oligomers. c) Sequence region in the C-terminal tail (CTT; not 
resolved in the structural studies) harbouring the site that upon phosphorylation by TANK-
binding kinase 1 (TBK1) binds interferon regulatory factor 3 (IRF3). d) Cartoon model depicting 
the events from 2ʹ,3ʹ-cGAMP binding to IRF3 activation. 2ʹ,3ʹ-cGAMP binds to the ligand-
binding pocket formed by the LBDs of the STING dimer. This is associated with a 180° clockwise 
rotation of its LBDs in relation to the transmembrane region, and this conformation change is 
suggested to generate a surface geometry that promotes lateral STING oligomerization. STING 
dimers associate — via their CTTs — with TBK1. Ligand binding and STING oligomerization 
appear to promote in trans phosphorylation of TBK1. Active TBK1 then phosphorylates the 
STING CTT (this occurs on an adjacent dimer of STING, rather than the dimer to which TBK1 is 
bound). CTT phosphorylation (P) creates a docking site for IRF3, which is subsequently 
phosphorylated by TBK1. IRF3 then dimerizes, gaining transcriptional activity. C-terminal, 
carboxy-terminal; ER, endoplasmic reticulum; ERGIC, ER–Golgi intermediate compartment. 
 
Fig. 5: Effector functions of STING. 
Stimulator of interferon genes (STING) functions as a dimer, which is formed at the 
endoplasmic reticulum (ER). Upon 2ʹ,3ʹ-cyclic GMP–AMP (2ʹ,3ʹ-cGAMP) binding, STING 
undergoes a conformational shift that results in the closure of its lid structure, a rotation of 
its ligand-binding domains (LBDs) in relation to its transmembrane domains (Fig. 4a,b), which 
favours oligomerization of active STING dimers in a side-to-side configuration. STING 
oligomers exit the ER towards the ER–Golgi intermediate compartment (ERGIC). a) As early as 
the ERGIC, STING oligomers facilitate TANK-binding kinase 1 (TBK1). Active TBK1 then 
phosphorylates Ser366 of the STING C-terminal tail (CTT), which serves as a docking site for 
interferon regulatory factor 3 (IRF3). IRF3 is then phosphorylated by TBK1, resulting in the 
formation of an active transcription factor complex (Fig. 4d). b)  Activation of NF-κB is either 
governed downstream of TBK1 activation, which requires the CTT of STING, or emanates from 
a yet to be identified signal from LBDs in STING in its active configuration. c) At the ERGIC, 
STING has been implicated in autophagy induction. Specifically, the STING-containing ERGIC 
has been shown to serve as a membrane source for autophagosome biogenesis, with cGAMP 
stimulation promoting lipidation of the key autophagosome biogenesis factor, LC3. This 
activity of STING is independent of its CTT or TBK1 activity, but the exact mechanism and 
contribution of STING to autophagy induction remain to be determined. d) After being routed 
through the Golgi, STING is trafficked through late endosomes to the lysosome. The exact 
topology of STING at or within the lysosome needs to be determined. Possible locations are 
at the outer lysosomal membrane or within multivesicular bodies (MVBs). In certain cell types 
(for example, human myeloid cells), lysosomal accumulation of STING leads to lysosomal 
membrane permeabilization, which subsequently results in a lytic form of cell death known as 
lysosome-dependent cell death and a secondary inflammatory response. Nevertheless, the 
primary role of directing STING to the lysosome seems to be its degradation, which limits the 
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Glossary 
Innate immune system 
A heterogeneous system of molecules, signal transducers and cells that has evolved to 
detect invading microbes, and elicits a first line of antimicrobial defence and activates 
the adaptive immune system. 
Pattern recognition receptors 
(PPRs). Germline-encoded receptors of the innate immune system. They detect 
pathogen or danger/damage-associated molecular patterns and elicit cellular defence 
reactions. 
Pathogen and damage-associated molecular patterns 
(PAMPs and DAMPs). Molecules that signal the presence of pathogens (that is, PAMPs) 
or danger/damage (that is, DAMPs). They are recognized by pattern recognition 
receptors. 
Adaptive immune system 
A branch of the immune system that comprises B and T lymphocytes. It elicits a highly 
specific response to antigens through highly variable, clonally expressed B cell 
receptors/antibodies or T cell receptors. 
Nucleotidyl transferase 
(NTase). A class of enzymes that transfer nucleoside phosphates onto an acceptor, 
typically a hydroxyl group. 
Cyclic dinucleotide 
Two nucleoside phosphates, joined in a circular dinucleotide through two 
phosphodiester linkages. Cyclic dinucleotides are found in prokaryotes and higher 
eukaryotes, and typically have second messenger functions to regulate diverse 
activities, such as bacterial biofilm and planktonic lifestyles (c-di-GMP), osmolyte 
homeostasis (c-di-AMP) and eukaryotic innate immune signalling (cyclic GMP–AMP). 
Cellular senescence 
A state that is generally characterized by a permanent cell cycle arrest in the context 
of ageing or tumour suppression. It can be promoted by multiple factors, including 
oxidative stress, DNA damage, mitochondrial dysfunction and the unfolded protein 
response. 
Aicardi–Goutières syndrome 
A rare, genetically determined progressive encephalopathy with autoimmune features 
that is caused by mutations in various genes involved in nucleic acid metabolism. 
Systemic lupus erythematosus 
A systemic, chronic, autoimmune disease that affects connective tissue of the kidneys, 
heart, lungs, brain, blood and skin. 
Liquid–liquid phase separation 
In cell biology, the separation of macromolecules (proteins, nucleic acids) into two 
liquid-like phases with high and low concentrations of the macromolecule. 
Major histocompatibility complex class II 
(MHC II). Surface molecules, typically found on antigen presenting cells such as 
dendritic cells, macrophages and B cells, that display peptides derived from 
extracellular proteins for interaction with immune cells. 
Dendritic cells 
Specialized antigen-presenting cells in a heterogeneous group that act as a link 
between the innate and adaptive immune system. They take up and process antigens 
and induce naive T lymphocyte activation and effector cell differentiation. 
Extracellular vesicles 
Secreted vesicles produced by many cell types, including tumour cells that can carry a 
wide variety of cellular components, including DNA, RNA, proteins and other 
molecules. They include two main subpopulations known as microvesicles and 
exosomes that differ in their mode of biogenesis (plasma membrane versus endosomal 
origin). 
Natural killer cells 
Cytotoxic effector lymphocytes of the innate immune system that play critical roles in 
antitumour and antimicrobial defence. 
BAK/BAX macropores 
Pores in the outer membrane of mitochondria, formed by the BAK and BAX proteins 
to trigger cytochrome c release and apoptosis. 
Effector caspases 
Proteinases activated through cleavage by initiator caspases (caspase cascade) that 
then proteolytically cleave many target proteins to execute apoptosis. 
Mitochondrial stress 
Pathophysiological conditions leading to mitochondrial DNA stress, mitochondrial 
unfolded protein response and stress signalling pathways. 
Nucleosomal arrays 
Sequences of regularly spaced nucleosomes along the DNA, typically found at gene 
bodies of eukaryotic chromosomes. 
Nucleosome core particles 
Histone protein octamers together with ~147 bp of tightly wrapped DNA, which is 
protected from nuclease digestion. 
Linker DNA 
DNA connecting two adjacent nucleosome core particles. This can range in length in 
different species, cell types and loci. 
Nuclear envelope blebbing 
The formation of membrane bulges at the nuclear envelope. At these sites, the 
membrane separates from the underlying lamina, allowing the chromatin to herniate 
and protrude into the bleb. In the event of membrane rupture, blebbing results in 
exchanging material between cytosol and nucleoplasm. 
Telomeres 
Specialized protective end structures of linear chromosomes, consisting of a repetitive 
DNA sequence and associated proteins. 
Senescence-associated cell cycle arrest 
The shortening of telomeres leading to a prolonged DNA damage response and check-
point activation to trigger a permanent cell cycle arrest, a hallmark of senescent cells. 
Dicentric chromosomes 
Chromosomes containing two centromeres formed through genome rearrangements. 
Alternative lengthening of telomeres 
(ALT). The telomerase-independent, recombination-dependent mode of extension of 
telomeres in cancer cells. 
Autophagy 
A regulated system in which the cell degrades unwanted cellular components by 
incorporation into autophagosomes followed by fusion with lysosomes. 
γ-H2AX 
The phosphorylation of histone 2A variant X at Ser139, leading to nucleosomes 
containing γ-H2AX. This mark is an early cellular response to DNA double-strand 
breaks, which serves in the recruitment of other repair factors. 
Poly-ADP ribose polymerase 1 
(PARP1). An enzyme that binds and marks DNA breaks by adding poly-ADP-ribose (PAR) 
onto itself and other targets. 
LINE1 
(Long interspersed nuclear element 1). A class I transposable element, typically 6 kb 
long, present in the genome of humans and some other organisms. LINE1 elements 
comprise around 17% of the human genome. 
Homologous recombination 
A DNA double-strand break repair pathway in which a DNA end is resected, and the 
resulting single-strand is extended on a homologous template 
Gap junctions 
Specialized cell–cell channels formed by juxtaposed connexon pores of adjacent cells, 
allowing the cytoplasmic exchange of small molecules and ions. 
TIMELESS 
A protein implicated in the circadian rhythm, replication and enhancing homologous 
recombination through interactions with different proteins. 
Non-homologous end-joining 
A DNA double-strand break repair pathway in which two DNA ends are directly ligated, 
often after limited processing by nucleases and DNA polymerases, in a pathway that 
depends on DNA-dependent protein kinase and DNA ligase IV. 
COPII coat complex 
A protein complex in the secretory pathway composed of five proteins that coats 
membrane vesicles transporting material from the endoplasmic reticulum to the Golgi 
apparatus. 
ER–Golgi intermediate compartment 
(ERGIC). An organellar structure that mediates trafficking between the endoplasmic 
reticulum (ER) and the Golgi apparatus. 
Palmitoylation 
A lipid modification of proteins through covalent attachment of palmitic acid, 
regulating different properties of proteins, such as membrane interaction, stability and 
trafficking. 
MAPK 
A type of protein kinase that transduces extracellular signals, such as growth factors, 
cytokines and mitogens, to cellular programmes, such as growth, differentiation, 
inflammation and others. 
LC3 
(Also known as microtubule-associated proteins 1A/1B light chain 3B). A protein that 
functions in substrate selection in autophagy and is used as a marker for 
autophagosomes. 
SAVI 
(STING-associated vasculopathy with onset in infancy). A rare autoinflammatory 
vasculopathy characterized by severe skin lesions and interstitial lung disease. 
NLRP3 inflammasome 
A multiprotein complex that initiates a pro-inflammatory cell death with the release of 








































NF-kB and MAP kinase activation
Signalling to bystander cells
Autophagy induction
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HUMAN 361 PELLISGMEKPLPLRTDFS 379
MOUSE 360 PRLLISGMDQPLPLRTDLI 378
PIG   360 PELLISGMEQPLPLRSDIF 378
RAT   361 PRLLISGMEQPLPLRTDLI 379
          *.******::*****:*: 
TBK1-binding motif (TBM)pLxIS motif
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Function Interaction Ref. 
cGAS 
NONO Associates with cGAS in the nucleus 
and facilitates sensing of HIV DNA 




PQBP1 Binds reverse-transcribed HIV-1 DNA 
and facilitates its detection by cGAS 




ZCCHC3 Enhances the binding of cGAS to 
dsDNA 
Direct interaction with the NTase fold 
(amino acids 213–382) and the C-terminal 
fragment (amino acids 383–522) of cGAS 
63
 
G3BP1 Enhances the binding of cGAS to 
dsDNA 
Interaction with the N-terminal domain 62 
STING 
STIM1 Retains STING at the ER under steady-
state conditions 
Direct interaction of STIM1 with 
transmembrane regions of STING 
161
 
IFI16 Facilitates recruitment of TBK1 to 
STING and its phosphorylation of 
STING 
Not tested 162 
TOLLIP Stabilizes STING on the ER under 
steady-state conditions 
Direct interaction of the C-terminal region of 




cGAS, cyclic GMP–AMP synthase; C-terminal, carboxy-terminal; dsDNA, double-stranded 
DNA; ER, endoplasmic reticulum; G3BP1, GTPase-activating protein SH3 domain-binding 
protein 1; IFI16, interferon-γ inducible protein 16; NONO, non-POU domain-containing 
octamer binding protein; NTase, nucleotidyl transferase; N-terminal, amino-terminal; 
PQBP1, polyglutamine binding protein 1; STIM1, stromal interaction molecule 1; STING, 
stimulator of interferon genes; TBK1, TANK-binding kinase 1; TOLLIP, Toll interacting protein; 
WW, protein interaction domain containing a signature double tryptophane motif; ZCCHC3, 
CCHC-type zinc-finger protein 3. 
 
Table 2 Regulation of cGAS and STING activity by post-translational modifications 
Site Location Type of PTM Enzyme Function Refs 
cGAS 
Asp140, Asp157 N-terminal 
domain 




Tyr215 Site A Phosphorylation Bruton’s 
tyrosine 
kinase 





Asp319 Active site metal 
coordinator 
Cleavage Caspase 3 Suppresses type I 
interferon signalling 
110,164 
Ser305 Active site Phosphorylation AKT Inhibits catalytic activity 109 
Lys347, Lys384, 
Lys394* 




Sumoylation Unknown Inhibits cGAS 114 
Desumoylation SENP7 Facilitates cGAS activity 
Lys231, Lys479 Site A (Lys231) 
Surface residue 
near active site 
(Lys479) 
Sumoylation TRIM38 Inhibits cGAS 113 
Desumoylation SENP2 Facilitates cGAS activity 
Glu286* Surface near site 
C (?) 
Glutamylation TTLL6 Inhibits DNA binding 165 
Deglutamylation CCP6 Promotes DNA binding 
Glu314* Surface near 
active site 













Acetylation Unknown Inhibits activity 111 
Deacetylation HDAC3 Promotes activity 
Lys414 Active site Ubiquitylation 
(Lys48) 






Increases cGAS protein 
stability 
Lys173, Lys384 Site A Ubiquitylation 
(Lys27) 




















Not tested Deubiquitylation 
(Lys48) 
USP27X Enhances stability 168 
STING 













TMD and LBD 
Ubiquitylation 
(Lys48) 






TMD and LBD 
Ubiquitylation 
(Lys63) 






TMD and LBD 
Ubiquitylation 
(Lys11) 













































Site Location Type of PTM Enzyme Function Refs 
Lys338 CTT near LBD 
attachment 








TMD and LBD 
Deubiquitylation 
(Lys48) 
CYLD Promotes stability 175 
Not tested NA Deubiquitylation 
(Lys27) 




All amino acid numberings are provided for the human protein. If studies in other species 
were conducted (designated*), the amino acid numbering of the homologous positions of 
the human protein is provided. AKT, RACα serine/threonine-protein kinase (also known as 
PKB); AMFR, autocrine motility factor receptor; CCP, cytosolic carboxypeptidase; cGAS, cyclic 
GMP–AMP synthase; CTT, C-terminal tail; CYLD, cylindromatosis; DHHC, named after Asp–
His–His–Cys sequence motif; HDAC3, histone deacetylase 3; IRF3, interferon regulatory 
factor 3; LBD, ligand-binding domain; MUL1, mitochondrial E3 ubiquitin protein ligase 1; NA, 
not applicable; PTM, post-translational modification; RNF, RING finger protein; SENP, 
sentrin/SUMO-specific protease; STING, stimulator of interferon genes; TBK1, TANK-binding 
kinase 1; TMD, transmembrane domain; TRIM, tripartite motif proteins; TTLL, tubulin-
tyrosine ligase-like; USP, ubiquitin specific peptidase. 
 
